Being essential for the human body, both products were one of DSM’s burdens. Q2 saw modest organic growth (+1%), but favourable FX rates and acquisition-related effects pushed sales upwards by +12% to €1,965m; including discontinued operations, sales came in at €2,515m (€2,288m). EBITDA was broadly unchanged at €254m, but rose +8% to €307m including discontinued operations. Net profit attributable to shareholders came in +28% higher at €97m.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Uneasy vitamin E and omega 3
- Published:
04 Aug 2015 -
Author:
Martin Schnee -
Pages:
3
Being essential for the human body, both products were one of DSM’s burdens. Q2 saw modest organic growth (+1%), but favourable FX rates and acquisition-related effects pushed sales upwards by +12% to €1,965m; including discontinued operations, sales came in at €2,515m (€2,288m). EBITDA was broadly unchanged at €254m, but rose +8% to €307m including discontinued operations. Net profit attributable to shareholders came in +28% higher at €97m.